Fast Company May 11, 2021
Legislators are untangling how to drive the development of important new drugs while also bringing down the cost of medications.
Congress is again attempting to control the overwhelming cost of drugs in the United States. Last week, government committees revived conversations about House Resolution 3 (H.R.3)—a bill that, if enacted, would give Medicare the ability to negotiate drug prices, cap out-of-pocket spending on medications, and fine drug manufacturers for increasing drug prices faster than the rate of inflation. The main argument against the bill is that it will curb drug industry profits, therefore limiting the industry’s ability to invest money in what it does best: innovating.
So do Americans have to sacrifice innovation to get cheaper drugs?
H.R.3 was first...
Today's Sponsors
Today's Sponsor